Results 101 to 110 of about 18,762 (211)

Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger, Kaitlyn Chan, Alphonsus Yip, Xingyue Maria Wang, Conor Broderick, Bernd Arents, Karin van Bart, Kilian Eyerich, Joseph Rastrick, Stephan Weidinger, Carsten Flohr, on behalf of the BIOMAP Consortium   +11 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Single‐Injection Multi‐Omics Analysis by Direct Infusion Mass Spectrometry

Angewandte Chemie, Volume 138, Issue 20, 11 May 2026.
A high‐throughput direct infusion mass spectrometry platform, enabled by gas‐phase ion mobility separation, supports single‐injection analysis of peptides, polar metabolites, and lipids. Coupled with custom software, it identified ∽1,300 proteins and ∽600 metabolites in ∽4.3 minutes per sample, and demonstrated broad utility in macrophage polarization ...
Yuming Jiang, Ivan Salladay‐Perez, Amanda Momenzadeh, Jesús Muñoz‐Estrada, Uktarsh Tripathi, Anthony J. Covarrubias, Jesse G. Meyer   +6 more
wiley   +2 more sources

Therapeutic Response of Alopecia Areata-Associated Nail Changes to Baricitinib

Case Reports in Dermatological Medicine
Nail changes are seen in some individuals with alopecia areata, with the most common variants including pitting and trachyonychia. The nail findings are presumed to be due to the same lymphocytic infiltration seen in hair bulbs in individuals with AA ...
Ashley Wittmer, Katherine De Jong, Lauren Bolish, Lindsey Finklea   +3 more
doaj   +1 more source

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience [PDF]

, 2023
Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved as monotherapy or in combination with methotrexate for treating adults with moderate-to-severe active rheuma-toid arthritis (RA) and provides improvements in clinical signs ...
Alten, Rieke, Choy, Ernest, De La Torre, Inmaculada, Feist, Eugen, Finckh, Axel, Haladyj, Ewa, Laedermann, Cedric, Richette, Pascal, Tanaka, Yoshiya, Taylor, Peter C   +9 more
core   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

From Sprinters to Marathoners: Rethinking Therapeutic Speed and Disease Modification in Atopic Dermatitis

Allergy, EarlyView.
Thomas Bieber, Felix Lauffer
wiley   +1 more source

Janus Kinase Inhibitors for the Treatment of Pediatric Morphea: A Systematic Review

Pediatric Dermatology, EarlyView.
ABSTRACT Morphea, also known as localized scleroderma (LoS), is an inflammatory, fibrosing dermatologic disorder of the skin and underlying tissues with associated comorbidities including joint contractures, limb‐length discrepancies, and inflammatory arthropathy occurring more commonly in children.
Alexa Moschella, Celina DeBiasio, Carmen Liy‐Wong   +2 more
wiley   +1 more source

Br J Haematol [PDF]

Activation of tyrosine kinase 2 (TYK2) contributes to the aberrant survival of T-cell acute lymphoblastic leukaemia (T-ALL) cells. Here we demonstrate the anti-leukaemic activity of a novel TYK2 inhibitor, NDI-031301. NDI-031301 is a potent and selective

core  

Calcinosis Cutis and Delayed‐Onset Myositis in a Case of Suspected Localized Scleroderma: A Diagnostic and Therapeutic Challenge

Pediatric Dermatology, EarlyView.
ABSTRACT A 16‐year‐old girl presenting with calcinosis cutis and localized scleroderma subsequently developed delayed‐onset idiopathic inflammatory myopathy five years after initial skin involvement. Despite the absence of typical dermatomyositis features and negative myositis‐specific antibodies, whole‐body MRI revealed extensive subclinical muscle ...
Edoardo Marrani, Laura Gatti, Ilaria Pagnini, Teresa Oranges, Cesare Filippeschi, Gabriele Simonini   +5 more
wiley   +1 more source